NOVEL NSAID FOR PARKINSON'S DISEASE
TRIAZIN ANALOGUE OF DICLOFENAC AS POTENTIAL LIGAND FOR PARKINSON'S: AN EXPERIMENTAL APPROACH
Versandkostenfrei!
Versandfertig in 6-10 Tagen
40,99 €
inkl. MwSt.
PAYBACK Punkte
20 °P sammeln!
Parkinson's disease (PD) is known to be the progressive loss of dopamine neurons in the substania nigra pars compacta, is one of the most prevalent neurodegenerative illnesses. The condition affects more than 1 million people in the US. The majority of instances are discovered in the sixth or seventh decade of life, and it often starts after the age of 50. NSAIDs may alter the risk of PD, according to studies. Diclofenac is one of those that is most frequently prescribed and is linked to serious GI toxicity. To increase the safety profile and the therapeutic window, synthetic methods based on ...
Parkinson's disease (PD) is known to be the progressive loss of dopamine neurons in the substania nigra pars compacta, is one of the most prevalent neurodegenerative illnesses. The condition affects more than 1 million people in the US. The majority of instances are discovered in the sixth or seventh decade of life, and it often starts after the age of 50. NSAIDs may alter the risk of PD, according to studies. Diclofenac is one of those that is most frequently prescribed and is linked to serious GI toxicity. To increase the safety profile and the therapeutic window, synthetic methods based on the chemical modification of diclofenac should be needs. This book covered NSAIDs and its role in PD management, and provide the synthetic approaches and preclinical evaluation report of diclofenac analogue.
Andere Kunden interessierten sich für
